Evidence map›Paper›PMID 26950204›Full record

Trial reportRejuvenation research2016

A Natural Product Telomerase Activator Lengthens Telomeres in Humans: A Randomized, Double Blind, and Placebo Controlled Study.

Laura Salvador, Gunasekaran Singaravelu, Calvin B Harley, Peter Flom, Anitha Suram, Joseph M Raffaele

Registry-linked trialAbstract readRandomized Controlled Trial
PubMed Full text at PMC Publisher
In one paragraph

Trial report in Rejuvenation research, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT05500742 (The proBNPage Reduction), which is not on this map. Cited by 52 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
52citing papers in PubMed, 2 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT05500742 naunknown statusnot on this mapstarted 2022, after this paper: background citation

The proBNPage Reduction (PBAR) Randomized Trial: a Pilot Study to Define the Characteristics of Future Randomized Trials Aimed at Evaluating the Effects of Anti-aging Treatments on a Surrogate of Biological Age in Healthy Older Adults

TypeinterventionalSponsorIRCCS Azienda Ospedaliero-Universitaria di BolognaRan2022 to 2024Enrolled120ConditionsAgingArmsCoenzyme Q10, Selenium, Resveratrol, TA-65 MD, Placebo-1
3 · Its place in the literature

Who cites it

52 citing papers in PubMed, 2 syntheses or guidelines pooled it.

  1. Pooled it
  2. Pooled it
  3. Trial
  4. Trial
  5. Review
  6. Biomolecules · 2026
    Review
  7. Review
  8. Review
  9. Review
  10. Review
  11. Review
  12. Review
  13. Article
  14. Review
  15. Review
  16. Review
  17. Article
  18. Review
  19. Review
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Laura Salvador1 Anti-aging Group Barcelona , Barcelona, Spain .
Gunasekaran Singaravelu2 T.A. Sciences, Inc. , New York, New York.
Calvin B Harley3 Independent Consultant , Murphys, California.
Peter Flom4 Peter Flom Consulting , New York, New York.
Anitha Suram2 T.A. Sciences, Inc. , New York, New York.
Joseph M Raffaele5 PhysioAge Systems, LLC , New York, New York.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

TA-65 is a dietary supplement based on an improved formulation of a small molecule telomerase activator that was discovered in a systematic screening of natural product extracts from traditional Chinese medicines. This study summarizes the findings on telomere length (TL) changes from a randomized, double blind, placebo controlled study of TA-65 over a 1 year period. The study was conducted on 117 relatively healthy cytomegalovirus-positive subjects aged 53-87 years old. Subjects taking the low dose of TA-65 (250 U) significantly increased TL over the 12 months period (530 ± 180 bp; p = 0.005), whereas subjects in the placebo group significantly lost TL (290 ± 100 bp; p = 0.01). The high dose of TA-65 (1000 U) showed a trend of improvements in TL compared with that of the placebo group; however, the improvements did not reach statistical significance. TL changes in the low-dose group were similar for both median and 20th percentile TLs. The findings suggest that TA-65 can lengthen telomeres in a statistically and possibly clinically significant manner.

Indexed as

Medicine, Chinese TraditionalAgedAged, 80 and overBiological ProductsCross-Sectional StudiesDose-Response Relationship, DrugDouble-Blind MethodEnzyme ActivationHumansMiddle AgedTelomeraseTelomereBiological ProductsTelomeraseAstragalusplacebo controlled trialrandomizedTA-65telomerasetelomere length

Identifiers

PMID26950204
PMCPMC5178008

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.